No Data
Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $90
Citi Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $70
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Calculating The Intrinsic Value Of Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Is There An Opportunity With Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) 26% Undervaluation?
Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment